A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag International NV
• Treatments: Paliperidone Palmitate

Criteria

Inclusion Criteria:

• Participants diagnosed with schizophrenia

• Participant admitted to hospital due to an exacerbation of their schizophrenia prior to any study-related activity

• Participant may, in the opinion of the participating physician, benefit from treatment with paliperidone palmitate which will be initiated within 3 weeks after admission to hospital

Exclusion Criteria:

• Participant has a known hypersensitivity to paliperidone or risperidone

• Participant has previously been treated with paliperidone palmitate

• Participant has a history of neuroleptic malignant syndrome

• Participant was on clozapine or has previously been treated with any long-acting injectable antipsychotic during the last 3 months